Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab Plus Irinotecan in Third-line Metastatic Colorectal Cancer
NCT00655499Phase 2Completed
- Sponsor
- GERCOR
- Start
- Jun 2008
- Primary completion
- Jun 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC), sponsored by GERCOR. Primary endpoint: Objective Response Rate up to 20 months. Started Jun 2008; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00655499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655499.